• Written by: (Investorideas.com newswire, breaking stock market
  • Tue, 27 Aug 2024
  •   United States

SAN DIEGO - August 27, 2024 (Investorideas.com Newswire) Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced the publication in preprint of an in vitro study in bioRxiv on August 24, 2024, entitled, "The Hemopurifier Removes Extracellular Vesicles and microRNAs From Renal Perfusates Following Controlled Oxygenated Rewarming of Discarded Donor Kidneys."

Breaking Medical Technology News: Aethlon Medical (NASDAQ: AEMD) Announces Publication of Preclinical Data Showing Ability of the Hemopurifier to Remove Extracellular Vesicles and microRNAs from Renal Perfusates Following Controlled Oxygenated Rewarming of Discarded Donor Kidneys